Background. Macrolides are used to treat pneumonia despite increasing antimicrobial
resistance. However, the immunomodulatory properties of macrolides may have a favorable …

Objective: Some studies suggest better outcomes with macrolide therapy for critically ill
patients with community-acquired pneumonia. To further explore this, we performed a …

The relative efficacy, safety and ecological implications of macrolides vs. quinolones in the
treatment of community-acquired pneumonia (CAP) are debatable. We performed a …

Background The choice of empirical antibiotic treatment for patients with clinically suspected
community-acquired pneumonia (CAP) who are admitted to non–intensive care unit (ICU) …

Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause
worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated …

Background: For years, monotherapy with a β-lactam antibiotic (penicillin, amoxicillin or
second-generation cephalosporin) was recommended as empirical therapy for patients with …

The present study compared β-lactam macrolide (“combination”) therapy versus β-lactam
alone (“monotherapy”) for hospitalised community-acquired pneumonia, using propensity …

It is unclear whether in the treatment of community‐acquired pneumonia (CAP) beta‐lactam
plus macrolide antibiotics lead to better survival than beta‐lactam alone. We report a …

OBJECTIVE: To evaluate adherence to guidelines when choosing an empirical treatment
and its impact upon the prognosis of community-acquired pneumonia (CAP). METHODS: A …

Importance Antibiotic therapy is the cornerstone of medical management for community-
acquired pneumonia. Objective To assess the associations between 3 key aspects of …